Literature DB >> 25663541

Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema.

Sibel Eyigör1, Ece Cinar, Ismail Caramat, Burcu Koc Unlu.   

Abstract

PURPOSE: In clinical practice, noticeable differences are seen in patient response to the treatment of breast cancer-related lymphedema. Although some factors influencing response to treatment are mentioned in the literature, there is no sufficient evidence and results are confusing. For this reason, our objective in this study is to identify predictive and response-related factors for response to treatment of breast cancer-related lymphedema.
METHODS: We analyzed data retrospectively from the files of patients with breast cancer-related lymphedema between 2006 and 2012. Patient demographics, clinical variables, and patient variables were recorded. Circumference measurements of lymphedema and healthy arms were recorded. We used a computer program (Limb Volumes Professional version 5.0) to transform these values to limb volumes in milliliters.
RESULTS: The average age of 331 patients was 54.4 ± 10.9. The average length of lymphedema treatment was 2.92 ± 1.3 weeks. A statistically significant positive correlation was found between postoperative weight gain and postoperative duration, number of chemotherapy (CT) cycles, duration of tamoxifen use, and duration of hormonal therapy (p < 0.05). There was a statistically significant negative correlation between posttreatment arm volume and activity level, postoperative duration, and postoperative weight gain (p < 0.05).
CONCLUSION: The treatment methods used for treating breast cancer had no effect on the response to treatment of lymphedema. Weight gain during the treatment of breast cancer is important for both the development of lymphedema and the response to treatment. When treating breast cancer-related lymphedema, the relationship between activity level and postoperative weight gain may provide us guidance in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663541     DOI: 10.1007/s00520-015-2633-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  Predictive factors of response to intensive decongestive physiotherapy in upper limb lymphedema after breast cancer treatment: a cohort study.

Authors:  Stéphane Vignes; Raphaël Porcher; Annick Champagne; Alain Dupuy
Journal:  Breast Cancer Res Treat       Date:  2006-07       Impact factor: 4.872

2.  Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica.

Authors:  F W STEWART; N TREVES
Journal:  Cancer       Date:  1948-05       Impact factor: 6.860

Review 3.  The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology.

Authors: 
Journal:  Lymphology       Date:  2013-03       Impact factor: 1.286

Review 4.  Arm edema in breast cancer patients.

Authors:  V S Erickson; M L Pearson; P A Ganz; J Adams; K L Kahn
Journal:  J Natl Cancer Inst       Date:  2001-01-17       Impact factor: 13.506

5.  The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of lymphedema severity and response to CDP in breast cancer-related lymphedema (BCRL).

Authors:  Su-Fen Liao; Shu-Hua Li; Hsin-Ya Huang; Shou-Tung Chen; Shou-Jen Kuo; Dar-Ren Chen; Ta-Sen Wei
Journal:  Breast       Date:  2013-01-12       Impact factor: 4.380

6.  The quality of life and social support in significant others of patients with breast cancer--a longitudinal study.

Authors:  P Salonen; A Rantanen; P-L Kellokumpu-Lehtinen; H Huhtala; M Kaunonen
Journal:  Eur J Cancer Care (Engl)       Date:  2013-11-18       Impact factor: 2.520

7.  Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil.

Authors:  Daniella M F Paiva; Vivian O Rodrigues; Marcelle G Cesca; Pamella V Palma; Isabel C G Leite
Journal:  BMC Womens Health       Date:  2013-02-13       Impact factor: 2.809

8.  Lymphedema after treatment of breast cancer.

Authors:  Cihangir Ozaslan; Bekir Kuru
Journal:  Am J Surg       Date:  2004-01       Impact factor: 2.565

9.  Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study.

Authors:  K Johansson; K Ohlsson; C Ingvar; M Albertsson; C Ekdahl
Journal:  Lymphology       Date:  2002-06       Impact factor: 1.286

10.  The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema.

Authors:  M B Tobin; H J Lacey; L Meyer; P S Mortimer
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

View more
  5 in total

1.  The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related-lymphedema.

Authors:  Dilek Keskin; Meltem Dalyan; Sibel Ünsal-Delialioğlu; Ülkü Düzlü-Öztürk
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-03

2.  Differences in limb volume trajectories after breast cancer treatment.

Authors:  Betty Smoot; Bruce A Cooper; Yvette Conley; Kord Kober; Jon D Levine; Judy Mastick; Kimberly Topp; Christine Miaskowski
Journal:  J Cancer Surviv       Date:  2015-12-18       Impact factor: 4.442

3.  Features, Predictors, and Treatment of Breast Cancer-related Lymphedema.

Authors:  Xiaochen Zhang; Jill M Oliveri; Electra D Paskett
Journal:  Curr Breast Cancer Rep       Date:  2020-09-09

4.  Effectiveness of Mobiderm® bandages in the treatment of cancer-related secondary lymphedema: A pilot study.

Authors:  Sung Cheol Cho; Sang Gyu Kwak; Hee Kyung Cho
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

5.  Clinical effectiveness of decongestive treatments on excess arm volume and patient-centered outcomes in women with early breast cancer-related arm lymphedema: a systematic review.

Authors:  Eunice Jeffs; Emma Ream; Cath Taylor; Debra Bick
Journal:  JBI Database System Rev Implement Rep       Date:  2018-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.